The United States launched military strikes against Iranian targets yesterday, a move President Trump characterised as a mere “carezza” – a caress – but which Tehran immediately denounced as a violation of the ceasefire. The attack injects fresh volatility into a region already on edge, though Washington has offered no immediate explanation of strategic objectives. Viewed from the Gulf, the escalation appears calibrated to test Iran’s red lines without triggering full-scale conflict, yet the risk of miscalculation remains high.

That same administration, meanwhile, suffered a significant legal setback on the trade front. A US Court of International Commerce ruled that the 10% tariffs imposed by Trump in February are unlawful, striking at the core of his protectionist agenda. The decision, which analysts in London describe as a rare judicial check on executive power over trade, casts doubt on the broader tariff architecture that has reshaped global supply chains. Whether the administration will appeal or seek legislative cover remains an open question.

As these dramas unfold in the political arena, commercial realignments continue apace. Stellantis announced it would deepen its partnership with Chinese electric vehicle maker Leapmotor, agreeing to produce a new SUV at plants in Madrid and Zaragoza. The move underscores the automotive industry’s race to integrate Chinese technology while navigating European regulatory demands and tariff uncertainty. For Madrid, it offers a vote of confidence in Spain’s manufacturing base.

On the healthcare front, two very different crises illustrate the global strain on access to treatment. In Brazil, the national health agency ANS has pioneered a new mechanism to secure price reductions for high-cost drugs, exemplified by its recent agreement with Sanofi over dupilumab for severe COPD. The model ties mandatory insurance coverage to manufacturer discounts, a pragmatic response to ballooning pharmaceutical costs that other nations may study.

In stark contrast, patients in Iran are abandoning treatment altogether. Reports reaching this desk indicate that prices for common neurological medications have surged between 30 and 380 percent since mid-April, with drugs like clonazepam and sertraline becoming scarce. The shortages, compounded by inflation and sanctions, have forced many to halt therapy – a humanitarian toll that, viewed from Tehran, is as acute as any missile strike.

These five disparate stories, from the Persian Gulf to the Iberian Peninsula, from the US judiciary to Brazilian and Iranian pharmacies, share a common thread: the fraying of systems under pressure. Whether through military force, legal challenge, industrial partnership, or healthcare rationing, the world is adjusting to a new landscape of heightened costs and diminished predictability. The coming months will test whether such adjustments can be sustained without deeper fractures.